Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based Iomai has signed an agreement with Merck & Co., to conduct proof-of-principle preclinical studies evaluating the use of the Iomai needle-free immunostimulant patch.
Subscribe to our email newsletter
Merck has the first option to negotiate an exclusive license. These preclinical proof-of-principle studies will be conducted using an undisclosed Merck vaccine.
Stanley Erck, president and CEO of Iomai, said: “This agreement with Merck allows us to further evaluate the possible applications of our patch. Our immunostimulant patch has the potential to improve the immune response to a wide variety of vaccines, allowing for more effective vaccines, or vaccines that work at a lower dose.”